These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 28944694)

  • 21. The totaled health risks in vascular events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial.
    Kamel H; Patel N; Rao VA; Cullen SP; Faigeles BS; Smith WS; Flint AC
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1111-6. PubMed ID: 23122722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
    Lee SH; Kim BJ; Han MK; Park TH; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Nah HW; Lee J; Lee SJ; Ko Y; Kim JG; Park JM; Kang K; Cho YJ; Hong KS; Choi JC; Kim JT; Choi K; Kim DE; Ryu WS; Kim WJ; Shin DI; Yeo M; Lee J; Lee JS; Gorelick PB; Bae HJ
    Int J Stroke; 2016 Oct; 11(7):783-90. PubMed ID: 27312681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current and future perspectives on the treatment of cerebral ischemia.
    Christophe BR; Mehta SH; Garton AL; Sisti J; Connolly ES
    Expert Opin Pharmacother; 2017 Apr; 18(6):573-580. PubMed ID: 28393614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue plasminogen activator (tPA) for acute ischaemic stroke: why so much has been made of so little.
    Hoffman JR
    Med J Aust; 2003 Oct; 179(7):333-4. PubMed ID: 14503891
    [No Abstract]   [Full Text] [Related]  

  • 25. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke.
    Fukuta T; Asai T; Yanagida Y; Namba M; Koide H; Shimizu K; Oku N
    FASEB J; 2017 May; 31(5):1879-1890. PubMed ID: 28082354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Thrombolytic therapy with tPA for the treatment of acute stroke. The Standard Treatment with Alteplase to Reverse Stroke study].
    Di Pasquale G
    Ital Heart J Suppl; 2000 Jul; 1(7):947-8. PubMed ID: 10935744
    [No Abstract]   [Full Text] [Related]  

  • 28. Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age.
    Arora R; Salamon E; Katz JM; Cox M; Saver JL; Bhatt DL; Fonarow GC; Peterson ED; Smith EE; Schwamm LH; Xian Y; Libman RB
    Stroke; 2016 Sep; 47(9):2347-54. PubMed ID: 27491734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke.
    Tung CE; Win SS; Lansberg MG
    Stroke; 2011 Aug; 42(8):2257-62. PubMed ID: 21719767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rescue localized intra-arterial thrombolysis for hyperacute MCA ischemic stroke patients after early non-responsive intravenous tissue plasminogen activator therapy.
    Kim DJ; Kim DI; Kim SH; Lee KY; Heo JH; Han SW
    Neuroradiology; 2005 Aug; 47(8):616-21. PubMed ID: 15983773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuries.
    Tsivgoulis G; Kargiotis O; Alexandrov AV
    Expert Rev Neurother; 2017 Aug; 17(8):819-837. PubMed ID: 28644924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses.
    Liao X; Wang Y; Pan Y; Wang C; Zhao X; Wang DZ; Wang C; Liu L; Wang Y;
    Stroke; 2014 Aug; 45(8):2354-8. PubMed ID: 25013020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke.
    Adams RJ; Cox M; Ozark SD; Kanter J; Schulte PJ; Xian Y; Fonarow GC; Smith EE; Schwamm LH
    Stroke; 2017 Mar; 48(3):686-691. PubMed ID: 28183857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire.
    Weintraub MI
    Stroke; 2006 Jul; 37(7):1917-22. PubMed ID: 16728683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
    Zhang Z; Zhang L; Yepes M; Jiang Q; Li Q; Arniego P; Coleman TA; Lawrence DA; Chopp M
    Circulation; 2002 Aug; 106(6):740-5. PubMed ID: 12163437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
    Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous rtPA thrombolysis in acute ischemic stroke.
    Laloux P
    Acta Neurol Belg; 2001 Jun; 101(2):88-95. PubMed ID: 11486563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.
    Schwamm LH; Ali SF; Reeves MJ; Smith EE; Saver JL; Messe S; Bhatt DL; Grau-Sepulveda MV; Peterson ED; Fonarow GC
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):543-9. PubMed ID: 24046398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Streamlined Hyperacute Magnetic Resonance Imaging Protocol Identifies Tissue-Type Plasminogen Activator-Eligible Stroke Patients When Clinical Impression Is Stroke Mimic.
    Goyal MS; Hoff BG; Williams J; Khoury N; Wiesehan R; Heitsch L; Panagos P; Vo KD; Benzinger T; Derdeyn CP; Lee JM; Ford AL
    Stroke; 2016 Apr; 47(4):1012-7. PubMed ID: 26892282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.
    Ning M; Furie KL; Koroshetz WJ; Lee H; Barron M; Lederer M; Wang X; Zhu M; Sorensen AG; Lo EH; Kelly PJ
    Neurology; 2006 May; 66(10):1550-5. PubMed ID: 16717217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.